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Interpretive Summary 1 
Prepartal high-energy feeding with grass silage-based diets does not disturb the hepatic adaptation of 2 
dairy cows during the periparturient period 3 
Qin, N. 4 
The effects of prepartal energy level on hepatic lipidome and transcriptome of dairy cows during the 5 
periparturient period were studied. Prepartal high-energy feeding elevated hepatic sphingolipid levels 6 
and downregulated hepatic inflammatory and acute phase responses one week prior to parturition. 7 
There was no evidence indicating that prepartal high-energy feeding disturbed hepatic adaptation. 8 
The findings will provide the basis of guidelines for nutritional management prepartum that will 9 
improve health and welfare in dairy cows during the periparturient period. 10 
  11 
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The liver of dairy cow naturally undergoes metabolic adaptation during the periparturient period in 25 
response to the increasing demand for nutrients. The hepatic adaptation is affected by prepartal energy 26 
intake level and is potentially associated with inflammatory responses. To study the changes in the 27 
liver function during the periparturient period, 16 cows (body condition score: 3.7 ± 0.3, mean ± SD; 28 
parity: second through fourth) were allocated to a grass silage-based controlled-energy diet (104 29 
MJ/day) or a high-energy diet (135 MJ/day) during the last 6 wk before the predicted parturition. 30 
Liver samples were collected by biopsy at 8 d prior to the predicted parturition (-8 d) and at 1 and 9 31 
d after the actual parturition (1 d and 9 d). The lipidomic profile of liver samples collected at -8 and 32 
9 d was analyzed using ultra performance liquid chromatography-mass spectrometry-based 33 
lipidomics. Liver samples from all the time points were subjected to microarray analysis and the 34 
subsequent pathway analysis with Ingenuity Pathway Analysis software. Prepartal energy intake level 35 
affected hepatic gene expression and lipidomic profiles prepartum, while little or no effect was 36 
observed postpartum. At -8 d, hepatic lipogenesis was promoted by prepartal high-energy feeding 37 
through the activation of X receptor/retinoid X receptor pathway and through increased transcription 38 
of thyroid hormone-responsive (THRSP). Hepatic inflammatory and acute phase responses at -8 d 39 
were suppressed (z-score = -2.236) by prepartal high-energy feeding through the increase in the 40 
mRNA abundance of suppressor of cytokine signaling 3 (SOCS3) and the decrease in the mRNA 41 
abundance of interleukin 1 (IL1), nuclear factor kappa B 1 (NFKB), apolipoprotein A1 (APOA1), 42 
serum amyloid A3 (SAA3), haptoglobin (HP), lipopolysaccharide binding protein (LBP), and inter-43 
alpha-trypsin inhibitor heavy chain 3 (ITIH3). Moreover, prepartal high-energy feeding elevated 44 
hepatic concentrations of C18- (7%), C20- (17%), C21- (26%), C23-sphingomyelins (26%), and total 45 
saturated sphingomyelin (21%). In addition, cows in both groups displayed increased lipogenesis at 46 
gene expression level after parturition and alterations in the concentration of various sphingolipids 47 
between the first and last samplings. In conclusion, prepartal high-energy feeding promoted 48 
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lipogenesis and suppressed inflammatory and acute phase responses in the liver before parturition, 49 
while only minor effects were observed after parturition. 50 






Dairy cows undergo a series of physiological adaptations during the periparturient period due to the 55 
increasing energy requirement and the subsequent negative energy balance. The physiological 56 
adaptations are partly mediated by insulin resistance (IR) and the change in plasma insulin 57 
concentration (Bell and Bauman, 1997). These changes lead to the mobilization of body reserves to 58 
the tissues in demand (Bell, 1995; Vernon, 2005). A part of mobilized nutrients are allocated to the 59 
liver, where they induce hepatic adaptation, including increased gluconeogenesis and ketogenesis 60 
(Aiello et al., 1984; Herdt, 2000). Hepatic adaptation is regulated at gene expression level as altered 61 
mRNA abundance near calving was observed in genes involved in various metabolic pathways (Loor 62 
et al., 2005; McCarthy et al., 2010). In addition, hepatic adaptation is potentially associated with the 63 
inflammatory status as negative energy balance is accompanied by increased inflammation induced 64 
by pro-inflammatory cytokines (Trevisi et al., 2012), which stimulate hepatic synthesis and secretion 65 
of positive acute phase proteins (Bionaz et al., 2007). 66 
Hepatic adaptation is potentially affected by prepartal energy intake level of cows. Prepartal high-67 
energy feeding has been reported to exacerbate the lipid mobilization from AT, particularly after 68 
parturition, as characterized by the elevated plasma non-esterified fatty acid (NEFA) level (Douglas 69 
et al., 2006; Janovick et al., 2011), and evidenced by the decreased expression of lipogenic genes in 70 
AT (Selim et al., 2015). As a consequence, the liver may be supplied with the excessive abundance 71 
of NEFA, which promotes hepatic lipogenesis and may lead to various metabolic disorders 72 
(Ingvartsen, 2006; Loor et al., 2006). Moreover, excessive energy intake prepartum and increased 73 
visceral adiposity may predispose dairy cows to inflammation and impaired liver function (Loor et 74 
al., 2006). In human and mice, inflammation is considered as a mechanism that induces IR (McArdle 75 
et al., 2013). However, there are controversial reports whether prepartal high-energy feeding (Mann 76 
et al., 2016; Salin et al., 2017) or increased adiposity (Shahzad et al., 2014; De Koster et al., 2015) 77 
leads to increased systemic IR in periparturient cows. 78 
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Sphingolipids are a class of lipids closely associated with the glucose homeostasis in human and mice 79 
(Larsen and Tennagels, 2014). Ceramides (Cer), the most abundant sphingolipids in the cell, have 80 
been recognized to trigger IR and their production is influenced by the inflammatory response 81 
(Chavez and Summers, 2012). In recent years, the application of lipidomics has enabled novel 82 
insights into the role of sphingolipids in the physiological adaptation in periparturient cows. Changed 83 
sphingolipid concentrations near calving were reported in the plasma, liver, AT, and skeletal muscle 84 
of cows (Imhasly et al., 2015; Qin et al., 2017; Rico et al., 2017). Comparisons between cows of 85 
different adiposity further suggested the associations between lipid mobilization and the 86 
concentrations of Cer, hexosyl ceramide (HexCer), and lactosylceramide in plasma and liver and the 87 
association between systemic IR and specific Cers during the periparturient period (Rico et al., 2015, 88 
2017). Moreover, prepartal high-energy feeding was reported to increase the concentration of specific 89 
Cers and the total concentration of sphingomyelin (SM) in AT near calving (Qin et al., 2017).  90 
We aimed to study effects of prepartal energy level on the hepatic adaptation of dairy cows during 91 
the periparturient period through the parallel analyses on global gene expression and lipidomic 92 
profiles. Firstly, we hypothesized that prepartal high-energy feeding increases hepatic lipogenesis. 93 
Secondly, we hypothesized that prepartal high-energy feeding increases hepatic Cer concentrations 94 
and upregulates genes related to inflammation during the periparturient period. 95 
MATERIALS AND METHODS 96 
Animals, Diets, Samplings, and Glucose Tolerance Tests 97 
The feeding experiment, feed composition, and collection of biopsies were described in detail in 98 
Selim et al. (2014). Sixteen Finnish Ayrshire dairy cows were involved in the feeding experiment in 99 
a randomized complete-block design. The cows were paired according to parity (second through 100 
fourth), body weight (693 ± 57 kg, mean ± SD), and body condition score (BCS; 3.7 ± 0.3, mean ± 101 
SD). The two cows in each pair were randomly allocated to two dietary treatment groups on 44 ± 5 d 102 
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(mean ± SD) prior to the actual parturition date. The grass silage-based dietary treatments included a 103 
controlled-energy (CON) diet (100% of the energy requirement of pregnant dairy cow; Luke, 2018) 104 
and a high-energy (HIGH) diet targeting to meet 150% of the energy requirement of a pregnant cow. 105 
In the ad libitum-fed HIGH group, the actual average energy intake was 144% of the energy 106 
requirement of pregnant dairy cow during the first 3 wk of experimental feeding. During the last 3 107 
wk before the predicted parturition, the energy allowance of the HIGH group was decreased by 5% 108 
on alternate days by gradually restricting DMI as described in more detail by Salin et al. (2017). The 109 
average ME was 99 MJ/d in the CON group and 141 MJ/d in the HIGH group from wk 6 to wk 4 110 
prepartum and 109 MJ/d in the CON group and 128 MJ/d in the HIGH group from wk 3 to wk 1 111 
prepartum. After parturition, all cows were fed wilted grass silage ad libitum, supplemented with 112 
increasing amount of small grain-based concentrate, starting from 5 kg/d on the day of parturition 113 
and increasing to 9 kg/d at 9 d postpartum (average ME 11 MJ/d during the first 2 weeks of lactation). 114 
The liver samples were collected by biopsy 8 d prior to the predicted parturition (11 ± 5 d in the actual 115 
operation) and 1 and 9 (± 1) d postpartum (the three time points are hereafter represented as -8 d, 1 116 
d, and 9 d ). Lipidomic and microarray analyses were conducted on 22 and 32 biopsy samples, 117 
respectively. The selection of samples was at random in respect of pairs to represent the design of the 118 
whole study. Intravenous glucose tolerance tests (IVGTT) were performed on the cows 10 ± 5 d 119 
(mean ± SD) prior to the actual parturition and 10 ± 1 d (mean ± SD) postpartum and the results have 120 
been published by Salin et al. (2017). The basal NEFA concentrations at 10 ± 5 d (mean ± SD) prior 121 
to the parturition and 10 ± 1 d postpartum were calculated by averaging the measurements on the 122 
blood samples collected 15 and 5 min before the IVGTT (Salin et al., 2017).  123 
Lipidomic Profiling 124 
Liver biopsies were pulverized using Covaris CryoPrep (Covaris Inc., Woburn, MA, USA) and an 125 
internal standard mixture containing examples of major lipid classes as esters with C17:0 fatty acid 126 
was added to the weighed aliquots of samples. Lipids were extracted (chloroform: methanol 2:1) with 127 
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Retsch Mixer Mill homogenizer (Retsch Gmbh, Haan, Germany). After extraction, a mixture 128 
containing three labeled standards was added in order to control the extraction process. The whole-129 
lipidome analyses were performed with a Waters quadrupole time-of-flight Premier mass 130 
spectrometer combined with an Acquity Ultra Performance LCTM (Waters Corp., Milford, MA, USA) 131 
by using an Acquity UPLCTM BEH C18 column (2.1 × 100 mm with 1.7 μm particles). The solvent 132 
system consisted of ultrapure water (1% 1 M NH4Ac, 0.1% HCOOH) and a mixture of acetonitrile: 133 
isopropanol (1:1, 1% 1M NH4Ac, 0.1% HCOOH). All solvents used were liquid chromatography-134 
mass spectrometry grade, and reference lipids were obtained from Avanti Polar Lipids, Inc. 135 
(Alabaster, AL, USA) and Larodan Fine Chemicals AB (Solna, Sweden). Quantification of all Cer, 136 
HexCer, and SM subspecies was based on the comparison with peak heights of internal standard Cer 137 
(d18:1/17:0). 138 
The data processing using MZmine 2 software included alignment of peaks, peak integration, 139 
normalization, and peak identification based on an internal spectral library. The analytical procedure 140 
was modified from that in Nygren et al. (2011), as described by Qin et al. (2017). The profiling of 141 
Cer and HexCer was carried out, using the negative-electrospray ionization mode, and the profiling 142 
of SM was carried out, using the positive-electrospray ionization mode. In total, 26 Cers, 6 HexCers, 143 
and 9 SMs were identified and quantified (µmol/g wet tissue) in the liver biopsies. 144 
Microarray Analysis 145 
Liver samples collected with biopsy were stored in a protective solution (Allprotect Tissue Reagent; 146 
Qiagen GmbH, Hilden, Germany) at -20 °C before total RNA extraction. Approximately 3-5 mg of 147 
liver was homogenized, using a TissueRuptor homogenizer (Qiagen). Total RNA was extracted with 148 
an RNeasy Mini Kit (Qiagen) according to the manufacturer’s instruction. 149 
Quantification of total RNA was performed with a NanoDrop 1000 spectrophotometer 150 
(ThermoFisher Scientific, Waltham, MA, USA). The quality of the RNA samples was assessed, using 151 
9 
 
an Agilent Bioanalyzer 2100 chip electrophoresis system and Agilent RNA 6000 Nano Kit (Agilent 152 
Technologies, Santa Clara, CA, USA). 153 
A total of 32 liver RNA samples were analyzed, using Affymetrix GeneChip® Bovine Genome Arrays 154 
(Affymetrix Inc., Santa Clara, CA, USA), including five, six, and six samples from the CON group 155 
and five, four, and six samples from the HIGH group at -8, 1, and 9 d, respectively. The arrays 156 
contained 24,027 probe sets, representing more than 23,000 transcripts. All RNA samples used in the 157 
array analyses showed RNA integrity number values higher than 8.9, and a total of 100 ng of RNA 158 
were used per array. All RNA samples and arrays were preprocessed, hybridized, and scanned by 159 
Biomedicum Genomics at the University of Helsinki. 160 
Since the amount of genomic sequence information has increased, the original annotations for the 161 
Affymetrix arrays were based on incomplete information. The annotations were supplemented by 162 
interrogating sequence databases and taking into account recent information (Cow Ensembl release 163 
86; National Center for Biotechnology Information (NCBI) Bos taurus Annotation Release 105). 164 
Calculations and Statistical Analyses 165 
The sphingolipid subspecies were further sorted and the concentrations were summed up, according 166 
to their fatty acid or sphingosine composition. The concentration of sphingolipids and further-sorted 167 
sphingolipid subclasses was log-2 transformed to normalize the data. The transformed data were 168 
imported into SAS (release 9.3; SAS Institute, Cary, NC, USA) for statistical analyses. The normality 169 
of residuals of the transformed data was tested with PROC MIXED and PROC UNIVARIATE 170 
procedures, using a model including diet as a fixed effect and pair as a random effect. The repeated-171 
measures ANOVA was performed using PROC MIXED procedure, in which treatment, time, and 172 
their interaction were set as fixed effects, pair and the interaction between pair and time were set as 173 
random effects, and animal was set as a within-subject effect. Three covariance structures were 174 
applied in the analyses, including compound symmetry (CS), unstructured (UN), and spatial power 175 
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(SP) law (POW). The structure giving the smallest Bayesian information criterion was eventually 176 
selected. The SLICE option of the PROC MIXED procedure was used to test the effect of diet within 177 
each time point. P-values lower than 0.05 were considered significant and those of 0.05 < P < 0.10 178 
represented tendencies toward significance. Heatmaps were composed based on the original 179 
concentration of all sphingolipid subspecies with MetaboAnalyst 3.0 (http://www.metaboanalyst.ca/, 180 
Xia Lab, McGill University; Xia et al., 2015). Spearman correlation analyses were performed 181 
between hepatic lipid concentrations, and the relative expression levels of selected hepatic genes 182 
obtained from the microarray analysis or the previous quantitative PCR (qPCR) analyses (Selim et 183 
al., 2014) and parameters from IVGTT (Salin et al., 2017) using PROC CORR procedure. 184 
The analysis of microarray data, including quality control, preprocessing, normalization, and 185 
statistical analysis, was carried out using R (https://www.r-project.org/), Bioconductor 186 
(https://www.bioconductor.org/), and Chipster software package (v. 3.9, CSC-IT Center for Science 187 
Ltd, Finland; Kallio et al., 2011). With Simpleaffy package in R software, a plot of quality-control 188 
metrics was performed for all 32 arrays to test the comparability of the scaling factors. Using Chipster 189 
software, we prepared an RNA degradation plot of all the arrays and spike-in-performance log-log 190 
plots of the signal intensity versus the RNA concentration for all 32 microarrays to further analyze 191 
the quality of the array hybridizations. The normalization was performed using the robust multiarray 192 
average method (Irizarry et al., 2003). The quality of the normalized data was evaluated with the box 193 
plots of the relative log expression and normalized unscaled standard error in Chipster. The variance 194 
in gene expression between the HIGH and CON groups was analyzed, using the local-pooled-error 195 
(LPE) test within the three time points (Jain et al., 2003). A false discovery rate control was performed 196 
on the P-values obtained, based on the method described by Benjamini and Hochberg (2000), 197 
generating a new dataset of adjusted P-values. The genes with adjusted-P < 0.05 were defined as the 198 
differentially expressed genes (DEG) between the two groups. The variance in gene expression over 199 
time was analyzed between all the time points (-8 vs. 1 d, 1 vs. 9 d, and -8 vs. 9 d), using the linear 200 
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model in Chipster, involving diet and time as the main effects after pairing the data from the same 201 
cow, followed by the same false-discovery rate control described above. Genes with adjusted-P < 202 
0.05 were considered to have different transcription levels between time points. The microarray data 203 
are available at the Gene Expression Omnibus page (https://www.ncbi.nlm.nih.gov/geo/) under 204 
accession number GSE97437. 205 
The microarray data were further analyzed with Ingenuity Pathway Analysis (IPA) System (v. 7.5; 206 
Ingenuity Systems, Mountain View, CA, USA; http://www.ingenuity.com). The input of the pathway 207 
analyses included DEGs identified in the microarray analysis and those identified in the previous 208 
qPCR with the analysis of variance between the CON and HIGH groups at all three time points (Selim 209 
et al., 2014). A dataset of DEGs, containing their gene symbols, P-values, and the log ratios of their 210 
expression in the HIGH group to that in the CON group, was imported into IPA. The genes in the 211 
dataset were mapped in IPA according to their gene symbols based on Ingenuity human and rodent 212 
knowledge base. The DEGs were grouped into canonical pathways, functions, and diseases, based on 213 
the right-tailed Fisher Exact Test, which is a measurement of the likelihood that the association 214 
between a set of DEGs in the experiment and a given process or pathway is due to random chance. 215 
Networks of the DEGs were composed, based on the connection between genes, as referenced from 216 
previous literature in the knowledge base. The networks were ranked according to their scores, 217 
calculated from the number of network eligible DEGs in one network, the total number of network 218 
eligible DEGs in the whole analysis, and the total number of molecules that potentially make up this 219 
network based on the knowledge base (Jiménez-Marín et al., 2009). 220 
RESULTS 221 
Sphingolipid Profiles in the Liver 222 
The most abundant Cer subspecies in the liver at -8 and 9 d were Cer (24:0), Cer (23:0), and Cer 223 
(22:0), taking up 23.6%, 21.3%, and 17.8% of the total Cer, respectively. Cer subspecies containing 224 
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an SFA comprised 86.7% of the total Cer, with the remainder containing a MUFA. From the aspect 225 
of sphingosine profiles, Cer (d18:1) represented 89.9% of the total Cer in the liver. Among SM, C16- 226 
and C23-SM were the top two abundant subclasses in the liver, comprising 43.0% and 31.4% of the 227 
total SM in concentration. Eighty-five percent of the SM contained an SFA, with those containing a 228 
MUFA forming the rest. 229 
The heatmap showed that higher level of sphingolipids tended to appear in the liver of the HIGH 230 
group than in the CON group at -8 d (Figure 1). In contrast, the difference in sphingolipid 231 
concentrations between the groups was much less apparent at 9 d. The further statistical analyses on 232 
sorted sphingolipid subclasses showed that the concentrations of Cer (23:0) (P = 0.088), Cer (23:1) 233 
(P = 0.099), Cer (24:1) (P = 0.080), and Cer (25:1) (P = 0.052) tended to be higher in the HIGH group 234 
compared with the CON group (Table 1). The comparison within time points showed that the different 235 
levels of Cer (24:1) (P = 0.020) and Cer (25:1) (P = 0.019) between groups were mainly contributed 236 
by the difference in their prepartal concentrations. None of the Cer subspecies differed in 237 
concentration after parturition. The majority of Cer subspecies displaying different concentrations 238 
between groups were MUFA-Cer, which is also shown by the tendency towards higher (P = 0.081) 239 
total MUFA-Cer concentration in the HIGH group than in the CON group (Table 1). In addition, 240 
prepartal high-energy feeding elevated the concentrations of C18- (P = 0.007), C20- (P = 0.004), 241 
C21- (P = 0.035), and C23-SM (P < 0.001), and the total concentration of saturated SM (P = 0.004) 242 
in the HIGH group compared with the CON group (Table 1). Similarly to Cers, the comparison within 243 
time points showed that the significant effect of prepartal high-energy feeding on SMs was mainly 244 
derived prepartum. 245 
Considering the change of sphingolipids in the liver over time regardless of the diet, the heatmap 246 
showed that the concentration of most HexCer and SM subspecies decreased from -8 to 9 d, with 247 
HexCer (d18:1/23:0), HexCer (d18:1/22:0), SM (d18:1/20:0), and SM (d18:1/21:0) being the 248 
exceptions (Figure 1). The patterns in Cer concentrations over time varied with the length of their 249 
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acyl chains. Moreover, the number of double-bonds in the acyl chain and the sphingosine type also 250 
influenced the patterns in Cer concentrations over time. For instance, we observed contrasting 251 
patterns over time between Cer (d18:1/20:0) and Cer (d18:2/20:0) and between Cer (d18:1/24:0) and 252 
Cer (d18:1/24:1). The further statistical analyses showed significant declines over time in a number 253 
of Cer subclasses, including Cer (18:0) (P = 0.042), Cer (23:1) (P = 0.014), Cer (25:1) (P = 0.025), 254 
Cer (26:0) (P < 0.001), and Cer (26:1) (P < 0.001; Supplemental Table S1). Exceptionally, an increase 255 
(P = 0.030) from -8 to 9 d was observed in Cer (23:0). From the aspect of sphingosine profiles, we 256 
observed significant increases in Cer (d17:1) (P = 0.044) and Cer (d18:0) (P = 0.014) concentrations 257 
whereas a decrease (P < 0.001) in Cer (d18:2) concentration from -8 to 9 d was observed 258 
(Supplemental Table S1). In addition, significant decreases over time were observed in various SM 259 
subclasses, including C16- (P = 0.037), C18- (P = 0.011), C24- (P = 0.036), and MUFA-SM (P = 260 
0.002).   261 
Pathway Analyses on DEGs between the Feeding Groups 262 
In the microarray analysis, we identified 106, 67, and 52 DEGs between the two groups at -8, 1, and 263 
9 d, respectively. Subsequently, IPA software successfully mapped 74 genes at -8 d, 43 genes at 1 d, 264 
and 36 genes at 9 d (Supplemental Table S2) and grouped these genes into pathways, functions, and 265 
diseases (Table 2). We identified 57, 52, and 29 pathways with P < 0.05 at -8, 1, and 9 d, respectively, 266 
in the canonical pathway analyses in IPA. Of these, only two pathways at -8 d displayed significant 267 
difference between the HIGH and CON group based on the calculation of z-score (Supplemental 268 
Figure S1), i.e. the downregulation of acute phase response signaling (z-score = -2.236; P < 0.0001; 269 
Supplemental Figure S2) and the upregulation of liver X receptor/retinoid X receptor (LXR/RXR) 270 
activation (z-score = 0.816; P < 0.0001; Supplemental Figure S3). The downregulation of acute phase 271 
response signaling was characterized by the upregulated transcription of suppressor of cytokine 272 
signaling 3 (SOCS3) and the downregulated transcription of interleukin 1 (IL1), nuclear factor kappa 273 
B 1 (NFKB1), apolipoprotein A1 (APOA1), serum amyloid A3 (SAA3), haptoglobin (HP), 274 
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lipopolysaccharide binding protein (LBP), and inter-alpha-trypsin inhibitor heavy chain 3 (ITIH3). 275 
The upregulation of LXR/RXR activation pathway was characterized by the upregulated transcription 276 
of apolipoprotein A4 (APOA4) and the downregulated transcription of APOA1, IL1, LBP, and 277 
NFKB1. In contrast, we observed no significant pattern in pathways at 1 and 9 d. In the network 278 
analyses, we identified two gene networks containing more than 20 DEGs, i.e. lipid metabolism, 279 
small-molecule biochemistry, and vitamin and mineral metabolism (score 51, 22 focus molecules) at 280 
-8 d and connective-tissue disorders, inflammatory disease, and skeletal and muscular disorders 281 
(score 53, 20 focus molecules) at 9 d. The network identified at -8 d displayed the association between 282 
the DEGs in the significant canonical pathways and other DEGs (Supplemental Figure S4).  283 
Changes in Gene Expression over Time 284 
We observed that 158 genes were differentially expressed for 1 d vs. -8 d. The numbers were 383 for 285 
9 d vs. 1 d and 654 for 9 d vs. -8 d (adjusted P < 0.05). The DEGs between time points involved in 286 
inflammatory response, acute phase response, sphingolipid metabolism, and lipogenesis were 287 
presented (Figure 2 and Figure 3).   288 
Correlation Analyses 289 
We observed negative correlations between BCS at 2 wk prepartum and the hepatic concentration of 290 
various Cer subclasses at -8 d, including Cer (18:0) (r = -0.79; P = 0.001), Cer (19:0) (r = -0.60; P = 291 
0.030), Cer (24:0) (r = -0.66; P = 0.014), Cer (25:1) (r = -0.60; P = 0.029), Cer (26:0) (r = -0.66; P = 292 
0.014), and Cer (26:1) (r = -0.77; P = 0.002). In addition, plasma NEFA concentration was negatively 293 
correlated with various Cer subclasses, e.g., Cer (18:0) prepartum (r = -0.63; P = 0.039) and Cer 294 
(16:0) postpartum (r = -0.77; P = 0.005). Glucose area under curve in IVGTT postpartum was 295 
negatively correlated with hepatic concentration of various Cer subspecies at 9 d, including Cer (18:0) 296 
(r = -0.64; P = 0.035), Cer (23:0) (r = -0.65; P = 0.029), Cer (24:0) (r = -0.80; P = 0.003) and Cer 297 
(25:0) (r = -0.72; P = 0.013). The relative expression level of SAA3 in microarray was negatively 298 
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correlated with hepatic C18-SM concentration at -8 d (r = -0.71; P = 0.047). The relative expression 299 
level of LBP in microarray was negatively correlated with hepatic concentrations of C16- (r = -0.74; 300 
P = 0.037) and C18-SM (r = -0.90; P = 0.002) at -8 d. The relative expression level of IL1A in 301 
microarray was negatively correlated with hepatic C20-SM concentration (r = -0.76; P = 0.028) at -302 
8 d.  303 
DISCUSSION 304 
This study presents the changes in hepatic lipidomic and gene expression profiles during the 305 
periparturient period in response to different prepartal energy intake levels. Parts of the results from 306 
the same experiment were published in earlier papers, including the whole-lipidome analyses in the 307 
liver and AT (Qin et al., 2017), the IVGTT results (Salin et al., 2017), the measurements of animal 308 
performance and blood metabolites, and the qPCR analyses of seven hepatic genes involved in insulin 309 
signaling, inflammatory response, and gluconeogenesis (Selim et al., 2014).  Despite the marked 310 
difference in energy intake between the two feeding groups, we found no diet effect in either BW 311 
change (1.3 vs. 1.1 kg/d; HIGH vs. CON) during the dry period or BCS before calving (3.7 vs. 3.8; 312 
HIGH vs. CON). However, we observed that the HIGH had lower basal blood NEFA concentration 313 
than the CON group in IVGTT at 1 wk prior to parturition (Salin et al., 2017). In contrast, the basal 314 
NEFA levels after parturition were not different between the feeding groups (Salin et al., 2017). In 315 
addition, results from IVGTT suggested little or no difference in whole-body insulin sensitivity 316 
between the HIGH and CON group at1 wk prior to parturition to 1 wk postpartum (Salin et al., 2017). 317 
Analogous to our previous results, the present results showed a greater effect of prepartal energy level 318 
on both the lipidomic and gene expression profiles before parturition than after.   319 
Hepatic lipogenesis 320 
Previously we reported that the HIGH group had higher hepatic total lipid concentration compared 321 
with the CON group at -8 and 9 d (Qin et al., 2017). At the gene expression level, the increase of total 322 
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lipid concentration under prepartal high-energy feeding was reflected by the upregulation of 323 
LXR/RXR activation pathway in the HIGH group compared with the CON group at -8 d because 324 
LXR/RXR activation is a pathway that promotes lipogenesis by stimulating sterol regulatory element-325 
binding protein 1c (Schultz et al., 2000). However, we observed no differential expression in the 326 
single genes of nuclear receptors LXR and RXR between groups, although the pathway was identified 327 
as significantly upregulated in the canonical pathway analysis. The increase in lipogenesis was 328 
supported by the upregulation of thyroid hormone-responsive (THRSP) in the HIGH group compared 329 
with the CON group at the same time point (Supplemental Figure S4). The gene THRSP promotes 330 
hepatic lipogenesis, and its expression is regulated by LXRα through a sterol regulatory element-331 
binding protein 1c-dependent mechanism in mice (Wu et al., 2013). The lipogenic role of THRSP 332 
was previously reported in the mammary epithelial cell of ruminants (Cui et al., 2015; Yao et al., 333 
2016). Previously, Khan et al. (2014) reported that high-energy feeding during the entire dry period 334 
increased hepatic transcription of various lipogenic genes before parturition, including THRSP. 335 
However, the difference in the feeding approaches between our study and Khan et al. (2014) may 336 
decrease the comparability between results. We gradually reduced the energy allowance in the HIGH 337 
group during the close-up period. This was not applied in Khan et al. (2014), although they observed 338 
a gradual decrease in DMI when approaching calving. Earlier studies have shown that the high energy 339 
intake during the far-off dry period is often associated with a decline of DMI during the close-up dry 340 
period and the decline has been up to 30% in corn silage-based diet (Grummer et al., 2004). This has 341 
led to the decreased difference in energy balance between the treatments with ad libitum and the 342 
controlled-energy feeding (Dann et al. 2006). Based on these findings, we manipulated the feed intake 343 
in the HIGH group by decreasing the energy allowance by 5% on alternate days through the gradual 344 
restriction of DMI during the last 3 wk before parturition (Salin et al., 2017), in order to test whether 345 
the high-energy feeding during the early dry period accompanied by a large decline of feed intake 346 
during the close-up dry period is detrimental to the physiological adaptation of dairy cows in grass 347 
17 
 
silage-based feeding. It is worth noting that the high-energy feeding still increased the average energy 348 
allowance by 30% compared with the control during the whole experimental period (135 MJ/day vs. 349 
104 MJ/day). Indeed, Dann et al. (2006) reported that the high-energy feeding during the far-off dry 350 
period had significant negative effects on the periparturient metabolism of dairy cows, whereas no 351 
effect was observed for the high-energy feeding during the close-up dry period. In the present study, 352 
the difference in energy intake between the HIGH (140% of CON during wk 6 and 4 prior to 353 
parturition) and CON group was profound during the far-off dry period. Therefore, we consider that 354 
it is profitable to compare our results with other high-energy feeding studies. 355 
As reported in our earlier publication, the HIGH group had lower plasma NEFA concentration 356 
prepartum compared with the CON group. Despite the decrease in plasma NEFA, the HIGH group 357 
displayed upregulated hepatic lipogenesis before parturition, based on the results from the microarray 358 
analysis. In the previous qPCR analyses on the same animals, we observed potentially suppressed 359 
fatty acid oxidation in the liver of the HIGH group compared with the CON group, based on the 360 
expression profile of carnitine palmitoyltransferase 1A (CPT1A; Selim et al. 2014), which encodes 361 
the CPT1 enzyme that facilitates the entry of fatty acids into mitochondria (Drackley et al., 2001). 362 
We suggest that the suppressed fatty acid oxidation under high-energy feeding may have outweighed 363 
the decrease in hepatic NEFA uptake and thus may have compensated for the lower influx of fatty 364 
acids in the liver, ultimately leading to the net increase in hepatic lipogenesis in the HIGH group 365 
compared with the CON group before parturition. The corresponding result was reported by Loor et 366 
al. (2006) showing that overfed cows had lower plasma NEFA levels and lower expression of genes 367 
related to hepatic fatty acid oxidation prepartum compared with cows in a restricted-energy diet. 368 
The stimulation of lipogenic pathways by the prepartal high-energy feeding disappeared after 369 
parturition. Moreover, the cows in the HIGH diet showed no greater lipid accumulation in the liver 370 
than did the cows in the CON diet after parturition (Qin et al., 2017). However, regardless of the diet, 371 
the cows displayed the accumulation of lipid in the liver after parturition, as suggested by the dramatic 372 
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increases in the concentration of triacylglycerol (TAG) and its precursor diacylglycerol (DAG) from 373 
-8 to 9 d (Qin et al., 2017). The lipid accumulation was reflected by the expression profiles of various 374 
lipogenic genes over time (Figure 3). The transcription of fatty acid transporters, including fatty acid 375 
binding protein 4 (FABP4) and solute carrier family 27 member A2 (SLC27A2), increased from 1 to 376 
9 d, suggesting a potential increase in hepatic NEFA uptake from the onset of lactation. A similar 377 
pattern was previously reported on another fatty acid transporter, showing that hepatic expression of 378 
solute carrier family 27 member A1 (SLC27A1) in dairy cows was higher at 1 wk postpartum than at 379 
3 wk prepartum (Gross et al., 2013). Increased NEFA influx after parturition may subsequently 380 
stimulate hepatic fatty acid oxidation, reflected by the upregulated hepatic transcription of carnitine 381 
palmitoyltransferase 1B (CPT1B) and carnitine palmitoyltransferase 1C (CPT1C) from -8 to 9 d. 382 
The activation of the CPT1-encoding genes after parturition corresponds to the previous findings of 383 
others (Drackley et al., 2005; Akbar et al., 2013; Khan et al., 2014). The transcription of fatty acid 384 
synthase (FASN) and diacylglycerol O-acyltransferase 2 (DGAT2) was higher at 9 d compared with 385 
-8 or 1 d, suggesting potentially increased hepatic fatty acid and TAG syntheses after parturition, in 386 
line with the finding of Gross et al. (2013), who observed that hepatic FASN expression increased 387 
dramatically from 3 wk prepartum to 1 wk postpartum. In the liver, TAG is stored as lipid droplets, 388 
with perilipins (PLIN) forming the surface. We observed higher expression of PLIN2 and PLIN3 at 389 
9 d relative to -8 d in both groups, which supports the increased TAG storage as lipid droplets in the 390 
liver after parturition and corresponds to the finding of Akbar et al. (2013) showing that hepatic 391 
PLIN2 expression in dairy cows increased from 14 d prepartum to 10 d postpartum. Collectively, the 392 
gene expression profiles reflected greater lipid storage and more active lipogenesis in the liver at 1 393 
wk postpartum than at 1 wk prior to parturition.  394 
Hepatic Inflammatory and Acute Phase Responses  395 
Prepartal high-energy feeding downregulated the acute phase response signaling pathway at -8 d 396 
based on the gene expression analysis. In cattle, acute phase response proteins have been defined as 397 
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indicators of inflammation and fatty liver disease (Nakagawa et al., 1997; Saremi et al., 2013). The 398 
downregulation of SAA3, HP, and LBP may reflect a lower grade of inflammation in the liver of the 399 
HIGH group than in the CON group at -8 d. This was supported by the downregulation of the pro-400 
inflammatory genes IL1 and NFKB1 in the HIGH group compared with the CON group at the same 401 
time point, because these genes participate in the mediation of the acute phase response, according to 402 
the findings in mice (Bode et al., 2012). Mouse studies have also suggested that SFA and 403 
lipopolysaccharides act as potential activators of toll-like receptor 4 (TLR4) and its downstream 404 
regulatory gene NFKB1 (Shi et al., 2006). The gene NFKB1 can stimulate the production of pro-405 
inflammatory cytokines, including IL1 (Shirasuna et al., 2016). Despite the absence of clear 406 
molecular mechanisms, increased expression of the genes encoding pro-inflammatory cytokines and 407 
acute phase proteins in the visceral fat was also observed when energy allowance of non-pregnant 408 
dairy cows was increased (Ji et al., 2014). Taken together with the lower plasma NEFA concentration 409 
compared with the CON group prepartum, we may speculate that the HIGH group had less SFA 410 
influx into the liver, leading to a lower grade of inflammation than in the CON group at 1 wk prior to 411 
parturition. 412 
Although prepartal high-energy feeding reduced hepatic inflammatory response at -8 d, the difference 413 
in inflammatory status disappeared after parturition. Considering the changes over time, we observed 414 
that cows in both groups displayed maximal hepatic expression of various cytokine receptors and 415 
acute phase proteins at 1 d, including interleukin 1 receptor type 2 (IL1R2), interleukin 4 receptor 416 
(IL4R), interleukin 10 receptor subunit beta (IL10RB), SAA3, serum amyloid A4 (SAA4), HP, and 417 
LBP (Figure 2). The results are in line with the observations by Loor et al. (2005) and Saremi et al. 418 
(2012, 2013), suggesting peaked cytokine signaling and acute phase response at parturition due to the 419 
systemic inflammation and tissue injury in the uterus. The increase of inflammation at parturition in 420 
both groups may have eliminated the difference in the inflammatory response between the two groups 421 
after parturition.  422 
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Previous findings suggested that high energy intake during the dry period resulted in negative effects 423 
on the performance and metabolism of dairy cows after parturition (Dann et al., 2006). However, we 424 
observed no impairment in the hepatic metabolism after parturition based on the gene expression 425 
profiles, as no pathway was significantly affected by the high-energy feeding at 1 and 9 d. The reason 426 
could be that the extent of the high-energy feeding in the present study was insufficient to induce a 427 
significant change in the adiposity of cows, as indicated by the similar BCS and systemic insulin 428 
sensitivity between the two groups around calving reported in our previous publications (Selim et al., 429 
2014; Salin et al., 2017). The adiposity of cows may act as an important factor that influences the 430 
liver function (Roche et al., 2015). Thus, the differences in hepatic metabolism between the groups 431 
in the present study may have been limited due to the similar adiposity. 432 
Hepatic Sphingolipid Profile and its Association with Inflammation 433 
The metabolism of Cer is closely associated with inflammation and IR according to the findings in 434 
mice (Chavez and Summers, 2012). Recently, associations between plasma and hepatic Cer and 435 
HexCer levels and insulin sensitivity were observed in dairy cows after parturition (Rico et al., 2015, 436 
2017). By comparing the Cer profiles between lean and overweight cows, Rico et al. (2017) found 437 
that after parturition plasma Cer (16:0) and Cer (24:0) levels were inversely associated with insulin 438 
sensitivity. In the present study, we observed negative correlations between BCS at 2 wk prepartum 439 
and the concentrations of various Cer subclasses at -8 d, suggesting that before parturition the 440 
potentially overweight cows may have lower hepatic Cer levels. Our observation corresponds to the 441 
finding of Rico et al. (2017), suggesting that overweight cows tended to have lower levels of Cer 442 
(16:0), Cer (24:0), and total Cer in the liver compared with lean cows before parturition.  443 
The concentrations of various SM subclasses were higher in the HIGH group compared with the CON 444 
group. SM hydrolysis is catalyzed by acid sphingomyelinase (ASMase). The enzyme ASMase was 445 
found to be activated in lipopolysaccharide-induced acute inflammation in mice (Wong et al., 2000), 446 
21 
 
and its activation was IL1-dependent (Jenkins et al., 2010). Moreover, a stimulatory effect of SFA on 447 
the activity of ASMase was observed in human cells, since it amplified the activation of TLR4-448 
induced inflammatory signaling (Jin et al., 2013; Lu et al., 2015). Collectively, the high-energy 449 
feeding of dry cows may have suppressed the hepatic inflammatory response through the 450 
downregulation of NFKB1 and IL1 expression by decreasing the hepatic SFA influx at -8 d, which 451 
subsequently reduced ASMase activity. As a consequence, the SM hydrolysis was decreased, 452 
resulting in higher hepatic SM concentrations in the HIGH group than in the CON group, as suggested 453 
by the negative correlation between IL1A expression and hepatic C20-SM concentration. In addition, 454 
the negative correlation between SAA3 expression and C18-SM concentration and that between LBP 455 
expression and the concentrations of C16- and C18-SM may further support the relationship between 456 
inflammation and SM hydrolysis.  457 
It is worth noting that negative correlations were also observed between the relative expression level 458 
of acute phase proteins (SAA3 and LBP) and the concentrations of several Cer subclasses containing 459 
very-long-chain or unsaturated fatty acids (MUFA-Cer, Cer (25:1), and Cer (24:1)), which appeared 460 
in higher concentrations in the HIGH group compared with the CON group similarly as SMs. 461 
Although there is evidence that several inflammation-related genes are regulated by a mechanism that 462 
involves Cer subspecies (Maceyka and Spiegel, 2014), the role of Cer subspecies in the hepatic 463 
metabolism is uncertain. The concentrations of total Cer and most Cer subclasses (with Cer (24:1) 464 
and Cer (25:1) being the exceptions) were not different between the two groups at -8 d in spite of the 465 
potentially lower SM hydrolysis in the HIGH compared with the CON group, suggested by the 466 
difference in SM concentrations (Qin et al., 2017). Thus, we suggest that the Cer production may 467 
have been supplied through other pathways, including the salvage pathway from other complex 468 
sphingolipids and the de novo synthesis from dietary nutrients (Merrill, 2011).  469 
In addition to the differences between groups, we observed the time-related differences in hepatic 470 
sphingolipid concentration regardless of the diet. The majority of Cer and SM subspecies that varied 471 
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over time displayed lower concentrations at 9 d relative to -8 d (Supplemental Table S1). Rico et al. 472 
(2017) reported increases in hepatic Cer (24:0) and total Cer concentrations in dairy cows during the 473 
periparturient period. However, the increases in Cer concentrations were mainly obvious in the 474 
overweight cows but not in lean cows. Rico et al. (2017) grouped the cows based on their BCS while 475 
in the present study prepartal high-energy feeding did not affect BCS before calving (Salin et al., 476 
2017), suggesting less difference in the adiposity between groups compared to Rico et al. (2017), 477 
which might explain the difference between results. 478 
The changes in sphingolipid concentrations over time were reflected in the expression of serine 479 
palmitoyltransferase small subunit A (SPTSSA) and serine palmitoyltransferase small subunit B 480 
(SPTSSB), which are two genes regulating the rate-limiting enzyme serine palmitoyltransferase 481 
(SPT) in Cer de novo synthesis (Han et al., 2009). Gene SPTSSB was expressed at lower levels at 9 482 
d relative to -8 d (Figure 2), corresponding to the patterns of most Cer subspecies over time, while 483 
the expression of SPTSSA increased after parturition, corresponding to the pattern of Cer (23:0) over 484 
time. The different expression patterns of the two SPT small subunits over time may suggest that 485 
these small subunits could have influenced the fatty acyl-CoA selectivity of SPT, as suggested by 486 
Han et al. (2009). Alternatively, the declines in most hepatic Cers over time may have resulted from 487 
the increased lipoprotein export of Cer when higher amount NEFA entered liver (Watt et al., 2012), 488 
as suggested by the negative correlation between plasma NEFA concentration and hepatic Cer 489 
concentrations postpartum. The increased hepatic export of Cer may occur to compensate plasma Cer 490 
level, as suggested by Rico et al. (2017), showing the elevation in plasma total Cer and Cer (24:0) 491 
concentrations after parturition. The exported Cer may contribute to the regulation of peripheral 492 
insulin sensitivity (Rico et al., 2015, 2017). The apparently contradictory negative correlation 493 
between hepatic Cer (24:0) and glucose area under curve in IVGTT after parturition may accentuate 494 





The effects of prepartal high-energy intake on the hepatic adaptation of dairy cows were reflected in 498 
gene expression and sphingolipid profiles prepartum, while postpartal hepatic gene expression and 499 
sphingolipid profiles were not affected. In the absence of change in body condition score, the 500 
observed prepartal effects were most likely due to the greater energy balance and decreased hepatic 501 
NEFA influx. Specifically, prepartal high-energy feeding increased hepatic lipogenesis before 502 
parturition by upregulating LXR/RXR pathway and lipogenic gene THRSP at gene expression level. 503 
Moreover, prepartal high-energy feeding suppressed hepatic inflammatory and acute phase responses 504 
before parturition, as supported by the downregulated expression of pro-inflammatory genes IL1 and 505 
NFKB1 and acute phase protein-coding genes SAA3, HP, and LBP. Subsequently, reduced 506 
inflammation in the liver may have contributed to the increased hepatic concentrations of C18-, C20-, 507 
C21-, C23-sphingomyelin, and total saturated sphingomyelin through the downregulation of 508 
sphingomyelin hydrolysis. Regardless of the diet, the cows displayed an increase in hepatic 509 
lipogenesis at gene expression level from 8 d prepartum to 9 d postpartum and decreases in the 510 
concentration of most ceramide and sphingomyelin subspecies detected in lipidomic analysis. 511 
Collectively, prepartal high-energy feeding did not disturb the hepatic adaptation of dairy cows during 512 
the periparturient period. 513 
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Table 1. Concentration of sphingolipid subclasses that showed significant difference (P < 0.05) or tendencies towards 708 
significant (P < 0.10) difference between the feeding groups at 8 d prior to parturition (-8 d) and 9 d postpartum (9 d). 709 
Lipid subclass 
  Mean2 
SEM 
P-value 
 CON HIGH Diet Day Diet × Day 
Cer (23:0)1 -8 d -2.02 -1.84 0.057 0.088 0.030 0.429 
   9 d -1.68 -1.66     
Cer (23:1) -8 d -3.97 -3.77 0.075 0.099 0.014 0.415 
   9 d -4.27 -4.24     
Cer (24:1) -8 d -3.60 -3.22 * 0.090 0.080 0.540 0.083 
 9 d -3.54 -3.41     
Cer (25:1) -8 d -5.31 -4.91 * 0.081 0.052 0.025 0.231 
 9 d -5.46 -5.34     
Saturated Cer -8 d -2.53 -2.22 0.076 0.081 0.066 0.161 
 9 d -2.63 -2.54     
SM (C18) -8 d -4.44 -4.23 † 0.062 0.007 0.011 0.542 
 9 d -4.60 -4.49     
SM (C20) -8 d -5.93 -5.62 * 0.093 0.004 0.281 0.541 
 9 d -5.70 -5.56     
SM (C21) -8 d -5.40 -4.97 † 0.106 0.035 0.506 0.624 
 9 d -5.21 -4.96     
SM (C23) -8 d -2.40 -1.93 * 0.078 <0.001 0.614 0.193 
 9 d -2.33 -2.13     
Saturated SM -8 d -0.86 -0.51 * 0.080 0.004 0.167 0.430 
 9 d -0.97 -0.78     
Label and abbreviations: HIGH, high-energy feeding group (targeted to 150% of the energy requirement of pregnant 710 
dairy); CON, controlled-energy feeding group (100% of the energy requirement of pregnant dairy cow); †,* ,** Statistical 711 
significance of the treatment effect is indicated in each row, † = P < 0.10; * = P < 0.05; ** = P < 0.01; SEM, standard 712 
error of the mean; Cer, ceramide; SM, sphingomyelin. 1. The content in the bracket indicates the fatty acid composition. 713 
2. The mean values in the table were log2-transformed from the original concentrations (μmol/g tissue).  714 
  715 
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Table 2. Summary of the most significant differentially expressed genes (DEGs), diseases, and 716 
biological functions in Ingenuity Pathway Analyses (IPAs). 717 
Analyses -8 d 1 d 9 d 
Top 5 upregulated 
molecules             
 Molecule Log2-fold Molecule Log2-fold Molecule Log2-fold 
 BOLA-DQB1 1.938 GNMT 1.736 BOLA-DQA2 1.447 
 BOLA-DQB2 1.484 BOLA-DQB1 1.551 BOLA-DQB1 1.343 
 MBOAT2 1.124 CRIP3 1.328 PRSS2 1.232 
 SLC11A1 1.108 EGR1 1.278 CYP11A1  0.922 
 SOCS3 1.040 CYP11A1 1.168 HP 0.843 
Top 5 
downregulated 
molecules       
 Molecule Log2-fold Molecule Log2-fold Molecule Log2-fold 
 S100A10 -1.878 BOLA-B -2.283 PCK1 -1.996 
 UGT3A1 -1.758 CPT1A -2.059 BOLA-B  -1.597 
 CPT1A -1.519 S100A10 -1.889 ASPA -1.503 
 SNCA -1.428 BOLA-DQA2 -1.889 CPQ -1.465 
 BOLA-B -1.416 SNCA -1.620 S100A10 -1.417 
Top 5 Disease 
and biological 
functions     




Molecular transport Inflammatory disease 
 
Vitamin and mineral 
metabolism 




Cellular function and 
maintenance 
Cell-to-cell signaling and 
interaction 
  Inflammatory diseases Cardiovascular disease Connective-tissue disorders 
 718 
BOLA-DQB1, histocompatibility complex, class II, DQ beta, type 1. BOLA-DQB2, 719 
histocompatibility complex, class II, DQ beta, type 2. MBOAT2, membrane-bound O-720 
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acyltransferase domain containing type 2. SLC11A1, solute carrier family 11 member A1.  SOCS3, 721 
suppressor of cytokine signaling 3. S100A10, S100 calcium-binding protein A10. UGT3A1, UDP 722 
glycosyltransferase family 3, polypeptide A1. CPT1A, carnitine palmitoyltransferase 1A. SNCA, 723 
synuclein alpha. BOLA-B, major histocompatibility complex, class I, B. GNMT, glycine N-724 
methyltransferase. CRIP3, cysteine-rich protein 3. EGR1, early growth response 1. CYP11A1, 725 
cytochrome P450, family 11, subfamily A, polypeptide 1. BOLA-DQA2, histocompatibility complex, 726 
class II, DQ alpha 2. PRSS2, protease, serine S2. HP, haptoglobin. PCK1, phosphoenolpyruvate 727 
carboxykinase 1. ASPA, aspartoacylase. CPQ, carboxypeptidase Q.  728 





Figure 1. Heatmap of sphingolipid concentrations in the controlled-energy (CON) feeding group and 732 
high-energy (HIGH) feeding group at 8 d prior to the predicted parturition (-8 d) and 9 d after the 733 
actual parturition (9 d). The concentration of sphingolipids was scaled based on their magnitude, 734 
represented by the intensity of grey color. Comparisons should be made within sphingolipid 735 
subspecies. The names of subspecies were formatted as sphingolipid type (sphingosine 736 
composition/fatty acid composition). Cer, ceramide. HexCer, hexosylceramide. SM, sphingomyelin. 737 
†,* ,** Statistical significance of the treatment effect is indicated in each row, † = P < 0.10; * = P < 738 








Figure 2. Normalized expression level of genes involved in ceramide metabolism, acute phase 745 
response, and inflammatory response at 8 d prior to the predicted parturition (-8 d), 1 d after the actual 746 
parturition (1 d), and 9 d after the actual parturition (9 d). The different letters indicate significant 747 
differences (P < 0.05). SPTSSA, serine palmitoyltransferase small subunit A. SPTSSB, serine 748 
palmitoyltransferase small subunit B. SAA3, serum amyloid A3. SAA4, serum amyloid A4. HP, 749 
haptoglobin. LBP, lipopolysaccharide-binding protein. IL1R2, interleukin 1 receptor type 2. IL4R, 750 







Figure 3. Normalized expression level of genes involved in lipid metabolism at 8 d prior to the 756 
predicted parturition (-8 d), 1 d after the actual parturition (1 d), and 9 d after the actual parturition (9 757 
d). The Different letters indicate significant differences (P < 0.05). FABP4, fatty acid binding protein 758 
4. SLC27A2, solute carrier family 27 member A2. CPT1B, carnitine palmitoyltransferase 1B. CPT1C, 759 
carnitine palmitoyltransferase 1C. DGAT2, diacylglycerol O-acyltransferase 2. FASN, fatty acid 760 
synthase. PLIN2, perilipin 2. PLIN3, perilipin 3. 761 
Supplemental Table S1.
Repeated-measures ANOVA of sphingolipid subclasses in the liver. 
CON HIGH Diet Day Diet×Day
Cer (16:0)1
      -8 d -3.21 -3.35 0.104 0.521 0.128 0.766
       9 d -3.49 -3.55
Cer (18:0)
      -8 d -4.46 -4.36 0.122 0.218 0.042 0.573
       9 d -4.92 -4.64
Cer (19:0)
      -8 d -7.44 -7.36 0.058 0.275 0.188 0.903
       9 d -7.56 -7.50
Cer (20:0)
      -8 d -5.70 -5.43 0.108 0.288 0.283 0.510
       9 d -5.39 -5.36
Cer (22:0)
      -8 d -2.22 -2.09 0.069 0.134 0.134 0.639
       9 d -1.98 -1.96
Cer (23:0)
      -8 d -2.02 -1.84 0.057 0.088 0.030 0.429
       9 d -1.68 -1.66
Cer (23:1)
      -8 d -3.97 -3.77 0.075 0.099 0.014 0.415
       9 d -4.26 -4.24
Cer (24:0)
      -8 d -1.81 -1.71 0.085 0.972 0.313 0.529
       9 d -1.56 -1.65
Cer (24:1)
      -8 d -3.60 -3.22 * 0.090 0.080 0.540 0.083
       9 d -3.54 -3.41
Cer (25:0)
      -8 d -3.81 -3.63 0.096 0.488 0.088 0.159
       9 d -3.87 -4.20
Cer (25:1)
      -8 d -5.31 -4.91 * 0.081 0.052 0.025 0.231
       9 d -5.46 -5.34
Cer (26:0)
      -8 d -3.27 -3.03 0.159 0.226 <0.001 0.865
       9 d -4.58 -4.25
Cer (26:1)
      -8 d -10.62 -10.31 0.126 0.191 <0.001 0.823
       9 d -11.63 -11.40
Saturated Cer
      -8 d 0.15 0.26 0.066 0.361 0.849 0.585
       9 d 0.24 0.22
MUFA-Cer
      -8 d -2.53 -2.22 * 0.076 0.081 0.066 0.161
       9 d -2.63 -2.54
Cer (d17:1)2
      -8 d -4.56 -4.34 0.067 0.327 0.044 0.572






      -8 d -5.38 -5.36 0.145 0.699 0.014 0.668
       9 d -4.63 -4.80
Cer (d18:1)
      -8 d 0.21 0.35 0.062 0.223 0.906 0.496
       9 d 0.27 0.26
Cer (d18:2)
      -8 d -4.08 -3.83 0.082 0.101 <0.001 0.659
       9 d -4.70 -4.56
SM  (C14)
      -8 d -6.26 -5.88 † 0.111 0.111 0.547 0.674
       9 d -6.28 -6.01
SM (C16)
      -8 d -1.75 -1.48 0.098 0.081 0.037 0.759
       9 d -2.06 -1.87
SM (C18)
      -8 d -4.44 -4.23 † 0.062 0.007 0.011 0.542
       9 d -4.60 -4.49
SM (C20)
      -8 d -5.93 -5.62 * 0.093 0.004 0.281 0.541
       9 d -5.70 -5.56
SM (C21)
      -8 d -5.40 -4.99 † 0.106 0.035 0.506 0.624
       9 d -5.21 -4.96
SM (C23)
      -8 d -2.40 -1.93 * 0.078 <0.001 0.614 0.193
       9 d -2.33 -2.13
SM (C24)
      -8 d -4.05 -4.21 0.104 0.631 0.036 0.284
       9 d -4.42 -4.35
Saturated SM
      -8 d -0.86 -0.51 * 0.080 0.004 0.167 0.430
       9 d -0.97 -0.78
MUFA-SM
      -8 d -3.33 -3.27 0.076 0.155 0.002 0.758
       9 d -3.69 -3.58
1. The content in the bracket indicates the fatty acid composition. 2. The content in the
bracket starting with d indicates the sphingosine composition. 3. The mean values in the
table were log2-transformed from the original concentrations (μmol/g tissue). 4. Label and
abbreviations: †,* ,** Statistical effects of diet in the same row, † = P < 0.10; * = P < 0.05;
** = P < 0.01; CON, controlled-energy feeding group; HIGH, high-energy feeding group;
SEM, standard error of the mean; Cer, ceramide; SM, sphingomyelin.
Supplemental Table S2.
Differentially expressed genes (DEGs) mapped in Ingenuity Pathway Analyses (IPAs) at different time points.




Bt.10056.1.S1_at Eukaryotic Translation Initiation Factor 2-Alpha Kinase 3 EIF2AK3 Down-regulated 7.00E-05 -0.632
Bt.10340.1.S1_at G Protein-Coupled Receptor 126 GPR126 Down-regulated 0.024505 -0.442
Bt.1201.1.A1_at Fetuin B FETUB Down-regulated 0.009479 -0.290
Bt.1229.1.S1_at Apolipoprotein A-I APOA1 Down-regulated 0 -0.622
Bt.12519.1.S1_at Flavin Containing Monooxygenase 3 FMO3 Down-regulated 0.007373 -1.400
Bt.12553.1.S1_at Haptoglobin HP Down-regulated 0 -1.036
Bt.12770.1.A1_at Synuclein, Alpha SNCA Down-regulated 0 -1.428
Bt.13367.1.A1_at X Inactive Specific Transcript XIST Down-regulated 0.008764 -0.340
Bt.13622.1.A1_at N/A LOC505099 Up-regulated 0.024878 0.606
Bt.13651.2.A1_at X-Prolyl Aminopeptidase (Aminopeptidase P) 2, Membrane-
Bound
XPNPEP2 Up-regulated 0.026712 0.608
Bt.13821.1.S1_at Adenylate Kinase 4 AK4 Down-regulated 0 -1.226
Bt.14572.1.A1_at Doublecortin-Like Kinase 1 DCLK1 Down-regulated 0.022095 -0.402
Bt.15748.1.A1_at Arv1 Homolog ARV1 Down-regulated 0.001794 -0.562
Bt.15842.1.S1_at Thyroid Hormone-Inducible Hepatic Protein Spot 14 THRSP Up-regulated 0.001116 0.874
Bt.15890.1.S1_at Apolipoprotein A-Iv APOA4 Up-regulated 0 0.296
Bt.16101.1.S1_at Granulysin GNLY Up-regulated 0.024327 0.136
Bt.16399.1.A1_at Betaine--Homocysteine S-Methyltransferase BHMT Down-regulated 0.006515 -0.628
Bt.16582.1.A1_at Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 CYP2C9 Up-regulated 0.000151 0.372
Bt.16621.1.A1_at Interleukin 1, Alpha IL1A Down-regulated 8.00E-05 -0.790
Bt.17368.1.A1_at Purinergic Receptor P2Y, G-Protein Coupled, 14 P2RY14 Down-regulated 3.80E-05 -0.340
Bt.17610.1.A1_at Chromosome 19 Open Reading Frame 80 C19orf80 Up-regulated 0.005072 0.438
Bt.18083.1.S1_at 3-Hydroxyacyl-Coa Dehydratase 4 PTPLAD2 Down-regulated 7.90E-05 -0.998
Bt.18231.1.S1_at Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 CYP2C9 Up-regulated 8.00E-06 0.702
Bt.18564.1.A1_at Alcohol Dehydrogenase 1C (Class I), Gamma Polypeptide ADH1C Up-regulated 0.007605 0.598
Bt.19822.1.A1_at Aldo-Keto Reductase Family 1, Member B10 AKR1B10 Up-regulated 0.015495 0.102
Bt.19825.1.S1_at Glucuronosyltransferase 2B17 UGT2B17 Down-regulated 3.50E-05 -1.030
Bt.1983.1.S1_at Egf-Like Module-Containing Mucin-Like Hormone Receptor-
Like 1
EMR1 Up-regulated 0.001005 0.732
Bt.20295.1.A1_at Follistatin FST Down-regulated 0.002145 -1.340
Bt.20989.1.S1_at Nicotinamide Nucleotide Adenylyltransferase 2 NMNAT2 Down-regulated 0 -1.066
Bt.2120.1.S1_at Carboxypeptidase Q CPQ Down-regulated 0.00131 -0.952
Bt.2120.2.S1_at Carboxypeptidase Q CPQ Down-regulated 0.008034 -0.918
Bt.21243.1.A1_at Inter-Alpha-Trypsin Inhibitor Heavy Chain 3 ITIH3 Down-regulated 0 -0.906
Bt.21997.1.S1_at Protein Phosphatase, Mg2+/Mn2+ Dependent, 1K PPM1K Down-regulated 0.000165 -0.696
Bt.22149.1.S1_at Family With Sequence Similarity 174, Member B FAM174B Down-regulated 4.80E-05 -0.730
Bt.22487.1.S1_at Alpha-2-Glycoprotein 1, Zinc-Binding AZGP1 Down-regulated 0.000182 -0.416
Bt.22487.3.S1_at Alpha-2-Glycoprotein 1, Zinc-Binding AZGP1 Up-regulated 7.50E-05 1.018
Bt.22763.1.S1_at 3-Hydroxy-3-Methylglutaryl-Coa Synthase 1 HMGCS1 Down-regulated 6.00E-05 -0.624
Bt.23042.1.S1_at Metallothionein 1A MT1A Down-regulated 0 -0.212
Bt.23094.4.S1_at Aldo-Keto Reductase Family 1, Member C3 AKR1C3 Up-regulated 0.015355 0.722
Bt.23204.1.S1_at Glutathione S-Transferase Theta 1 GSTT1 Up-regulated 6.80E-05 0.848
Bt.23992.1.A1_at Adenylate Kinase 4 AK4 Down-regulated 0 -1.092
Bt.24181.1.S1_at Lipopolysaccharide Binding Protein LBP Down-regulated 0.00613 -0.506
Bt.24570.1.S1_at N-Acylethanolamine Acid Amidase NAAA Up-regulated 2.00E-05 0.718
Bt.24600.1.S1_at Suppressor Of Cytokine Signaling 3 SOCS3 Up-regulated 0.000398 1.040
Bt.25303.1.A1_at N/A LOC100336669Up-regulated 0.002632 0.702
Bt.2592.1.A1_x_at Mhc Class I Heavy Chain BOLA Up-regulated 0.01779 0.178
Bt.27066.1.A1_at Insulin Receptor Substrate 1 * IRS1 *3 Down-regulated 0.1 -0.539
Bt.278.1.S1_at Serum Amyloid A1 SAA1 Down-regulated 0 -0.838
Bt.28011.1.S1_at Major Histocompatibility Complex, Class Ii, Drb3 BOLA-DRB3 Up-regulated 6.00E-05 1.252
Bt.28208.1.S1_at Fructose-1,6-Bisphosphatase 2 FBP2 Down-regulated 0 -0.740
Bt.28243.1.S1_a_at Vanin 1 VNN1 Up-regulated 0.015483 0.634
Bt.28521.1.S1_at Annexin A13 ANXA13 Down-regulated 4.00E-06 -0.722
Bt.2859.1.A1_at Set Domain Containing 9 SETD9 Up-regulated 0.010502 0.912
Bt.28878.1.S1_at Aspartoacylase ASPA Down-regulated 0 -1.368
Bt.2896.1.A1_at Glutathione S-Transferase M1 GSTM1 Up-regulated 1.60E-05 0.540
Bt.29660.1.A1_at Hydroxysteroid (17-Beta) Dehydrogenase 4 HSD17B4 Up-regulated 0.001335 0.492
Bt.29815.1.A1_at Mhc Class I Heavy Chain BOLA Down-regulated 0.001868 -0.320
Bt.29815.1.S1_x_at Mhc Class I Heavy Chain BOLA Down-regulated 0 -1.416
Bt.3115.1.A1_at Aspartylglucosaminidase AGA Down-regulated 0 -0.434
Bt.3311.1.S1_at N/A LOC101903901Up-regulated 0.038588 0.486
Bt.350.1.S1_at Histocompatibility Complex, Class Ii, Dq Beta, Type 1 BOLA-DQB1 Up-regulated 0 0.822
Bt.350.1.S1_x_at Histocompatibility Complex, Class Ii, Dq Beta, Type 1 BOLA-DQB1 Up-regulated 0 0.510
Bt.3809.1.S1_at Lactate Dehydrogenase A LDHA Down-regulated 0.016101 -0.668
Bt.3862.1.S1_a_at Peroxisome Proliferator-Activated Receptor Gamma * PPARG * Down-regulated 0.09 -1.264
Bt.4137.1.A1_at G0/G1 Switch 2 G0S2 Up-regulated 0.03592 0.516
Bt.4314.1.S1_at Annexin A2 ANXA2 Down-regulated 0.000105 -0.534
Bt.4391.1.S2_at Solute Carrier Family 2 (Facilitated Glucose Transporter),
Member 4
GLUT4 Down-regulated 0.1 -1.742
Bt.4594.1.S1_at Mhc Class Ii Antigen BLA-DQB Up-regulated 0 1.938
Bt.4751.1.S1_a_at Major Histocompatibility Complex, Class Ii, Dq Alpha 2 BOLA-DQA2 Up-regulated 0 1.484
Bt.4751.2.S1_a_at Major Histocompatibility Complex, Class Ii, Dq Alpha 2 BOLA-DQA2 Up-regulated 0 0.726
Bt.4802.1.S1_at Lactotransferrin LTF Up-regulated 0.000104 1.012
Bt.4852.1.S1_at Glutathione S-Transferase M1 GSTM1 Up-regulated 0.00039 0.554
Bt.4939.1.S1_at Secreted Frizzled-Related Protein 2 SFRP2 Down-regulated 0 -0.284
Bt.5037.1.S1_at S100 Calcium-Binding Protein A10 S100A10 Down-regulated 0 -1.580
Bt.5037.1.S2_at S100 Calcium-Binding Protein A10 S100A10 Down-regulated 0 -1.878
Bt.5329.1.S1_at Transmembrane Protein 254 TMEM254 Down-regulated 0.003086 -0.480
Bt.5329.2.S1_at Transmembrane Protein 254 TMEM254 Down-regulated 0.001794 -0.424
Bt.5362.2.S1_a_at Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase,
Antitrypsin), Member 3
SERPINA3-7 Down-regulated 0.004468 -0.170
Bt.5373.1.S1_at Solute Carrier Family 11 (Proton-Coupled Divalent Metal Ion
Transporter), Member 1
SLC11A1 Up-regulated 0.000524 1.108
Bt.628.1.S1_at Transmembrane Emp24 Protein Transport Domain
Containing 6
TMED6 Up-regulated 0.000103 0.510
Bt.647.1.S1_at Myotrophin MTPN Up-regulated 0.003822 0.562
Bt.6636.1.S1_at Udp Glycosyltransferase 3 Family, Polypeptide A1 UGT3A1 Down-regulated 0.004702 -1.758
Bt.7033.2.S1_a_at Folate Receptor 1 FOLR1 Down-regulated 0.006555 -0.462
Bt.7033.2.S1_at Folate Receptor 1 FOLR1 Down-regulated 0.020289 -0.418
Bt.7056.1.S1_at Hemoglobin Delta HBB Up-regulated 0 0.830
Bt.8669.1.S1_at Membrane Bound O-Acyltransferase Domain Containing 2 MBOAT2 Up-regulated 0 1.124
Bt.8669.2.S1_at Membrane Bound O-Acyltransferase Domain Containing 2 MBOAT2 Up-regulated 0 1.104
Bt.9289.2.S1_at Carnitine Palmitoyltransferase 1A * CPT1A * Down-regulated 0.04 -1.519
Bt.9309.1.A1_at Nuclear Factor Kappa B1 * NFKB1 * Down-regulated 0.04 -1.177
Bt.9569.1.S1_at Epithelial Cell Adhesion Molecule EPCAM Up-regulated 0.001794 0.202
Bt.9699.1.S1_at Cytochrome P450, Family 26, Subfamily A, Polypeptide 1 CYP26A1 Down-regulated 0.002145 -0.222
Bt.9807.1.S1_at Glycoprotein (Transmembrane) Nmb GPNMB Up-regulated 0.001335 0.878
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Bt.12768.1.S1_at Phosphoenolpyruvate Carboxykinase 1 * PCK1 * Down-regulated 0.006 -1.520
Bt.12770.1.A1_at Synuclein, Alpha SNCA Down-regulated 0 -1.620
Bt.13821.1.S1_at Adenylate Kinase 4 AK4 Up-regulated 0.000171 0.891
Bt.15890.1.S1_at Apolipoprotein A-Iv APOA4 Down-regulated 0 -1.216
Bt.17195.1.A1_at N/A LOC100139000Up-regulated 0.013176 0.270
Bt.17242.1.A1_at Cytochrome P450, Family 2, Subfamily B, Polypeptide 6 CYP2B6 Down-regulated 0 -1.363
Bt.20432.1.S1_at
Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 8 SERPINB8 Down-regulated 0.002371 -0.978
Bt.20919.2.A1_at Glycine N-Methyltransferase GNMT Up-regulated 0 1.736
Bt.20919.3.S1_at Glycine N-Methyltransferase GNMT Up-regulated 4.00E-05 1.398
Bt.20989.1.S1_at Nicotinamide Nucleotide Adenylyltransferase 2 NMNAT2 Down-regulated 4.40E-05 -0.888
Bt.21113.1.S1_a_at Carnitine Palmitoyltransferase 1B (Muscle) CPT1B Down-regulated 0.001235 -1.141
Bt.2120.1.S1_at Carboxypeptidase Q CPQ Down-regulated 6.00E-06 -1.125
Bt.2120.2.S1_at Carboxypeptidase Q CPQ Down-regulated 2.20E-05 -1.198
Bt.215.1.S1_at 2 BOLA-DQA2 Down-regulated 0 -1.603
Bt.22265.1.S1_at Early Growth Response 1 EGR1 Up-regulated 0 1.278
Bt.22487.3.S1_at N/A LOC100848227Down-regulated 0 -1.177
Bt.22629.1.A1_at Chromosome 21 Open Reading Frame 62 C21orf62 Down-regulated 0.002005 -1.119
Bt.22694.1.A1_at Apolipoprotein A-V APOA5 Down-regulated 0.019349 -0.762
Bt.2282.1.S1_a_at Cysteine-Rich Protein 3 CRIP3 Up-regulated 0.000755 1.328
Bt.22867.2.A1_at 1 BOLA-DQA1 Down-regulated 0.002057 -0.238
Bt.23042.1.S1_at Metallothionein 1A MT1A Up-regulated 0 1.058
Bt.23514.1.S1_at Alpha-2-Macroglobulin A2M Up-regulated 0.005514 0.861
Bt.23992.1.A1_at Adenylate Kinase 4 AK4 Up-regulated 0.006441 0.881
Bt.24199.1.A1_s_at Serpin Peptidase Inhibitor, Clade A UTMP Up-regulated 0 1.456
Bt.24293.1.A1_at Betaine--Homocysteine S-Methyltransferase BHMT Down-regulated 0.006441 -0.484
Bt.24813.1.A1_at N/A LOC532442 Up-regulated 0.005647 0.687
Bt.24827.1.A1_at N/A LOC509808 Down-regulated 1.00E-06 -1.506
Bt.25099.1.A1_at Phosphoserine Phosphatase PSPH Up-regulated 4.90E-05 0.983
Bt.25669.1.S1_at Mucolipin 2 MCOLN2 Up-regulated 0.000903 1.033
Bt.27066.1.A1_at Insulin Receptor Substrate 1 * IRS1 * Up-regulated 0.03 0.103
Bt.27645.1.A1_at Isthmin 1, Angiogenesis Inhibitor ISM1 Down-regulated 0.004 -1.488
Bt.28208.1.S1_at Fructose-1,6-Bisphosphatase 2 FBP2 Down-regulated 0 -0.852
Bt.28278.1.S1_at Angiotensin I Converting Enzyme 2 ACE2 Down-regulated 0.017581 -1.053
Bt.28521.1.S1_at Annexin A13 ANXA13 Down-regulated 0.001291 -1.238
Bt.28744.1.S1_at Guanylate Binding Protein 4 GBP4 Up-regulated 0.014035 0.957
Bt.28965.1.A1_at Signal Sequence Receptor, Alpha SSR1 Up-regulated 0.012769 0.880
Bt.29087.1.S1_at Atp-Binding Cassette, Sub-Family G (White), Member 8 ABCG8 Up-regulated 0.041267 0.870
Bt.29345.1.A1_at Dead (Asp-Glu-Ala-Asp) Box Polypeptide 10 DDX10 Down-regulated 0.012769 -1.278
Bt.29815.1.S1_x_at Major Histocompatibility Complex, Class I, B BOLA-B Down-regulated 0 -2.283
Bt.350.1.S1_at Histocompatibility Complex, Class Ii, Dq Beta, Type 1 BOLA-DQB1 Up-regulated 0 1.091
Bt.350.1.S1_x_at Histocompatibility Complex, Class Ii, Dq Beta, Type 1 BOLA-DQB1 Up-regulated 6.70E-05 1.054
Bt.3551.1.S1_at Solute Carrier Family 17 (Vesicular Nucleotide Transporter),
Member 9
SLC17A9 Up-regulated 0.008889 1.070
Bt.4404.1.A1_at Protease, Serine, 2 (Trypsin 2) PRSS2 Up-regulated 0 0.950
Bt.4594.1.S1_at Histocompatibility Complex, Class Ii, Dq Beta, Type 1 BOLA-DQB1 Up-regulated 0 1.551
Bt.4751.1.S1_a_at 2 BOLA-DQA2 Up-regulated 0 1.399
Bt.5037.1.S1_at S100 Calcium-Binding Protein A10 S100A10 Down-regulated 0.000124 -1.551
Bt.5037.1.S2_at S100 Calcium-Binding Protein A10 S100A10 Down-regulated 0 -1.889
Bt.5318.1.S1_at Retinol Binding Protein 4 * RBP4 * Down-regulated 0.03 -0.091
Bt.5970.1.S1_a_at S100 Calcium Binding Protein A2 S100A2 Up-regulated 0.015226 0.923
Bt.7190.1.S1_at Cytochrome P450, Family 11, Subfamily A, Polypeptide 1 CYP11A1 Up-regulated 4.90E-05 1.168
Bt.7490.1.A1_at Methylenetetrahydrofolate Dehydrogenase (Nadp+
Dependent) 1-Like
MTHFD1L Down-regulated 0 -0.918
Bt.9289.2.S1_at Carnitine Palmitoyltransferase 1A * CPT1A * Down-regulated 0.02 -2.059
Bt.9309.1.A1_at Nuclear Factor Kappa B1 * NFKB1 * Down-regulated 0.03 -1.192
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Bt.10371.1.S1_at Cysteine Sulfinic Acid Decarboxylase CSAD Up-regulated 0.027375 0.428
Bt.12339.1.S1_at Pyruvate Carboxylase PC * Down-regulated 0.03 -1.767
Bt.12553.1.S1_at Haptoglobin HP Up-regulated 0 0.843
Bt.12768.1.S1_at Phosphoenolpyruvate Carboxykinase 1 PCK1 * Down-regulated 0.06 -1.996
Bt.13622.1.A1_at N/A LOC505099 Up-regulated 1.10E-05 0.837
Bt.16399.1.A1_at Betaine--Homocysteine S-Methyltransferase BHMT Down-regulated 0 -0.993
Bt.17242.1.A1_at Cytochrome P450, Family 2, Subfamily B, Polypeptide 6 CYP2B6 Down-regulated 0 -1.115
Bt.17368.1.A1_at Purinergic Receptor P2Y, G-Protein Coupled, 14 P2RY14 Down-regulated 0.000881 -0.303
Bt.18083.1.S1_at 3-Hydroxyacyl-Coa Dehydratase 4 PTPLAD2 Down-regulated 0.026846 -0.525
Bt.2091.1.S1_at Dna-Damage-Inducible Transcript 4 DDIT4 Down-regulated 0.015038 -0.480
Bt.20989.1.S1_at Nicotinamide Nucleotide Adenylyltransferase 2 NMNAT2 Down-regulated 0 -0.568
Bt.21048.1.S1_at Lim Domain Binding 3 LDB3 Down-regulated 0.000498 -0.638
Bt.21048.2.S1_at Lim Domain Binding 3 LDB3 Down-regulated 1.00E-05 -0.640
Bt.2120.1.S1_at Carboxypeptidase Q CPQ Down-regulated 0 -1.388
Bt.2120.2.S1_at Carboxypeptidase Q CPQ Down-regulated 0 -1.465
Bt.21883.1.S1_at Placenta-Specific 8 PLAC8 Up-regulated 0.001849 0.463
Bt.21997.1.S1_at Protein Phosphatase, Mg2+/Mn2+ Dependent, 1K PPM1K Down-regulated 0.001242 -0.358
Bt.22629.1.A1_at Chromosome 21 Open Reading Frame 62 C21orf62 Down-regulated 0.026846 -0.522
Bt.22867.2.A1_at 1 BOLA-DQA1 Down-regulated 0 -0.645
Bt.23093.1.S1_at Chemokine (C-X-C Motif) Ligand 2 CXCL2 Down-regulated 0.002128 -0.445
Bt.23204.1.S1_at Glutathione S-Transferase Theta 1 GSTT1 Up-regulated 0.011498 0.677
Bt.25669.1.S1_at Mucolipin 2 MCOLN2 Up-regulated 0.00936 0.655
Bt.278.1.S1_at Serum Amyloid A1 SAA1 Down-regulated 5.20E-05 -1.008
Bt.28208.1.S1_at Fructose-1,6-Bisphosphatase 2 FBP2 Down-regulated 0.000881 -0.412
Bt.28278.1.S1_at Angiotensin I Converting Enzyme 2 ACE2 Down-regulated 0.001676 -0.668
Bt.28521.1.S1_at Annexin A13 ANXA13 Down-regulated 0 -1.140
Bt.28878.1.S1_at Aspartoacylase ASPA Down-regulated 0 -1.503
Bt.29815.1.S1_x_at Major Histocompatibility Complex, Class I, B BOLA-B Down-regulated 0 -1.597
Bt.350.1.S1_at Histocompatibility Complex, Class Ii, Dq Beta, Type 1 BOLA-DQB1 Up-regulated 0 0.870
Bt.350.1.S1_x_at Histocompatibility Complex, Class Ii, Dq Beta, Type 1 BOLA-DQB1 Up-regulated 0 0.738
Bt.3551.1.S1_at Solute Carrier Family 17 (Vesicular Nucleotide Transporter),
Member 9
SLC17A9 Up-regulated 9.00E-06 0.837
Bt.3809.1.S1_at Lactate Dehydrogenase A LDHA Down-regulated 0.003635 -0.348
Bt.4169.1.A1_at Conglutinin CGN1 Up-regulated 0.028848 0.362
Bt.4404.1.A1_at Protease, Serine, 2 (Trypsin 2) PRSS2 Up-regulated 0 1.232
Bt.4594.1.S1_at Histocompatibility Complex, Class Ii, Dq Beta, Type 1 BOLA-DQB1 Up-regulated 0 1.343
Bt.4751.1.S1_a_at Major Histocompatibility Complex, Class Ii, Dq Alpha, Type
2 BOLA-DQA2 Up-regulated 0 1.447
Bt.4751.2.S1_a_at Major Histocompatibility Complex, Class Ii, Dq Alpha, Type
2 BOLA-DQA2 Up-regulated 0.000311 0.752
Bt.4939.1.S1_at Secreted Frizzled-Related Protein 2 SFRP2 Down-regulated 9.00E-06 -0.357
Bt.5037.1.S1_at S100 Calcium-Binding Protein A10 S100A10 Down-regulated 0 -1.162
Bt.5037.1.S2_at S100 Calcium-Binding Protein A10 S100A10 Down-regulated 0 -1.417
Bt.6800.1.A1_at Rasgef Domain Family, Member 1B RASGEF1B Down-regulated 0.001035 -1.043
Bt.7190.1.S1_at Cytochrome P450, Family 11, Subfamily A, Polypeptide 1 CYP11A1 Up-regulated 2.00E-06 0.922
Bt.7490.1.A1_at Methylenetetrahydrofolate Dehydrogenase (Nadp+
Dependent) 1-Like
MTHFD1L Down-regulated 8.00E-06 -0.623
Bt.9289.2.S1_at Carnitine Palmitoyltransferase 1A * CPT1A * Down-regulated 0.08 -1.594
1. The P-values of the DEGs identified in the microarray were obtained from local-pooled-error (LPE) tests within time points, followed by a
false-discovery rate control. The P-values of the DEGs identified in quantitative polymerase chain reactions (qPCRs) were obtained from
repeated-measures ANOVA. 2. Log2-fold was calculated as that of the high-energy (HIGH) feeding group relative to the controlled-energy
(CON) feeding group. 3. The genes marked with an asterisk (*) are from quantitative reverse transcriptase-polymerase chain reaction (qRT-
PCR) analyses.
Supplemental Figure S1. 
Summary of canonical pathway analyses in Ingenuity Pathway Analysis (IPA). The lengths of the bars indicate the probability of significant upregulation or downregulation of the 
pathways. Significant pathways were marked in color, with orange representing upregulation in the high-energy (HIGH) feeding group versus controled-energy (CON) feeding 
group and blue representing downregulation in HIGH versus CON. The node on each bar indicates the ratio of the diferentialy expressed genes (DEGs) involved in the pathway 
in the dataset to the total number of genes involved in the pathway.
Supplemental Figure S2.
Acute phase response signaling pathway in Ingenuity Pathway Analysis (IPA). Diferentialy expressed genes (DEGs) in the dataset 
were marked in color, with red representing upregulation in the high-energy (HIGH) feeding group versus controled-energy (CON) 
feeding group.
feeding group.Supplemental Fig. S5.
Supplemental Figure S3.
Liver X receptor/retinoid X receptor (LXR/RXR) activation pathway in Ingenuity Pathway Analysis (IPA). Diferentialy expressed genes (DEGs) in the dataset were marked in color, with red representing upregulation in the high-energy (HIGH) feeding group versus controled-energy (CON) feeding group.
Supplemental Figure S4.
Network: lipid metabolism, smal-molecule biochemistry, and vitamin and mineral metabolism. The network is displayed graphicaly as 
nodes (genes). The solid lines indicate direct interaction between genes. The dashed line indicates indirect interaction between genes. 
The node color intensity indicates the expression of genes, with red representing upregulation and green downregulation in the high-en-
ergy (HIGH) feeding group relative to the controled-energy (CON) feeding group.
